Pages that link to "Q46455509"
Jump to navigation
Jump to search
The following pages link to Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma (Q46455509):
Displaying 50 items.
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents (Q21198868) (← links)
- Monitoring the effect of belinostat in solid tumors by H4 acetylation (Q24644030) (← links)
- Epigenetics of cervical cancer. An overview and therapeutic perspectives (Q24812104) (← links)
- Epigenetic treatment of solid tumours: a review of clinical trials (Q26773803) (← links)
- Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma (Q26851166) (← links)
- New and emerging HDAC inhibitors for cancer treatment (Q27022413) (← links)
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (Q29615649) (← links)
- Clinical Toxicities of Histone Deacetylase Inhibitors (Q31135325) (← links)
- Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients (Q33249818) (← links)
- Limited proteolysis of human histone deacetylase 1 (Q33259445) (← links)
- Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid (Q33274378) (← links)
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. (Q33390876) (← links)
- Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart (Q33392979) (← links)
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies (Q33439519) (← links)
- The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells (Q33584049) (← links)
- A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas (Q33619776) (← links)
- Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer (Q33651762) (← links)
- A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors (Q33732128) (← links)
- Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay (Q33793209) (← links)
- Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells (Q33827019) (← links)
- Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells (Q33831971) (← links)
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia (Q33844751) (← links)
- Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials (Q33849805) (← links)
- Combination therapy in combating cancer (Q33914234) (← links)
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers (Q34107482) (← links)
- Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis (Q34152949) (← links)
- Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. (Q34171631) (← links)
- Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices. (Q34268182) (← links)
- The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. (Q34334999) (← links)
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies (Q34414452) (← links)
- Epigenetic drugs against cancer: an evolving landscape (Q34431964) (← links)
- Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling (Q34559028) (← links)
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours (Q34621838) (← links)
- Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay (Q34656429) (← links)
- Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? (Q35001132) (← links)
- Interpreting clinical assays for histone deacetylase inhibitors (Q35003657) (← links)
- Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition (Q35005604) (← links)
- HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. (Q35070712) (← links)
- A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. (Q35634068) (← links)
- The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study (Q35674823) (← links)
- Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. (Q35696415) (← links)
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias (Q35750919) (← links)
- Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects (Q35939690) (← links)
- Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. (Q36052572) (← links)
- The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats. (Q36077200) (← links)
- An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers (Q36110047) (← links)
- Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors (Q36408642) (← links)
- Histone deacetylation as a target for radiosensitization (Q36510514) (← links)
- Targeting epigenetic abnormalities with histone deacetylase inhibitors (Q36529933) (← links)
- Assays for pharmacodynamic analysis of histone deacetylase inhibitors (Q36546255) (← links)